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Central line-associated blood stream infections (CLABSI) commonly complicate the care of patients with acute
myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic stem cell transplantation
(HCT). We developed a modiﬁed CLABSI (MCLABSI) deﬁnition that attempts to exclude pathogens usually
acquired because of disruption of mucosal barriers during the vulnerable neutropenic period following HCT
that are generally included under the original deﬁnition (OCLABSI). We conducted a retrospective study of all
AML and MDS patients undergoing HCT between August 2009 and December 2011 at the Cleveland Clinic
(N ¼ 73), identifying both OCLABSI and MCLABSI incidence. The median age at transplantation was 52 years
(range, 16 to 70); 34 had a high (3) HCT comorbidity index (HCT-CI); 34 received bone marrow (BM), 24
received peripheral stem cells (PSC), and 15 received umbilical cord blood cells (UCB). Among these 73
patients, 23 (31.5%) developed OCLABSI, of whom 16 (69.6%) died, and 8 (11%) developed MCLABSI, of whom 7
(87.5%) died. OCLABSI was diagnosed a median of 9 days from HCT: 5 days (range, 2 to 12) for UCB and 78 days
(range, 7 to 211) for BM/PSC (P < .001). MCLABSI occurred a median of 12 days from HCT, with similar earlier
UCB and later BM/PSC diagnosis (P ¼ .030). Risk factors for OCLABSI in univariate analysis included CBC
(P < .001), human leukocyte antigen (HLA)-mismatch (P ¼ .005), low CD34þ count (P ¼ .007), low total
nucleated cell dose (P ¼ .016), and non-Caucasian race (P ¼ .017). Risk factors for OCLABSI in multivariable
analysis were UCB (P < .001) and high HCT-CI (P ¼ .002). There was a signiﬁcant increase in mortality for both
OCLABSI (hazard ratio, 7.14; CI, 3.31 to 15.37; P < .001) and MCLABSI (hazard ratio, 6.44; CI, 2.28 to 18.18;
P < .001). CLABSI is common and associated with high mortality in AML and MDS patients undergoing HCT,
especially in UCB recipients and those with high HCT-CI. We propose the MCLABSI deﬁnition to replace the
OCLABSI deﬁnition, given its greater precision for identifying preventable infection in HCT patients.
 2013 American Society for Blood and Marrow Transplantation.BACKGROUND
Hospital-acquired infections occur in 5% of hospitalized
patients. Hospital-acquired bloodstream infections afﬂict
250,000 patients annually [1]. Central line-associated blood
stream infections (CLABSI) are a subset of blood stream
infections that are particularly dangerous, with a mortality
rate of 12% to 25% [1,2]. There were 19,000 CLABSI in inten-
sive care unit (ICU) patients and 23,000 CLABSI in patients
hospitalized in non-ICU settings in 2009 [1]. This equates to
a median incidence of 1.14 CLABSI (varying from 0.2 to 4.2
infections across institutions) per 1,000 catheter days in non-
ICU patients [1,3]. Recent quality initiatives have decreasededgements on page 724.
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18,000 in 2009, a reduction of 58% [1]. Other interventions in
the ICU have been associated with a reduction of CLABSI by
as much as 66% to 68% [4,5]. Non-ICU patients, who account
for over one-half of documented CLABSI, are not as well
studied [1]. This population includes patients with hemato-
logic malignancies undergoing allogeneic stem cell trans-
plantation (HCT), who have inherently compromised
immune function at baseline because of their malignancy,
which is further incapacitated secondary to treatment,
including both the transplantation preparative regimen and
immunosuppression to prevent graft-versus-host disease
(GVHD). Central venous catheter (CVC) placement and other
intravascular procedures predispose to CLABSI; however,
blood stream infections can also arise from disruption of
mucosal barriers by mucositis and GVHD of the gastroin-
testinal tract and skin.Transplantation.
Table 1
Patient Demographics, Past Therapies, Stem Cell Characteristics, and
Outcome of Transplantation
Variable No. of Subjects
Gender
Male 48 (65.8)
Female 25 (34.2)
Race
White 68 (93.2)
Black 3 (4.1)
Asian, American Indian 2 (2.8)
Age in years at transplantation, median (range) 52 (16-70)
Prior transplantation
Myeloablative 3 (4.1)
Autologous 2 (2.7)
Mini-allogeneic 1 (1.4)
None 67 (91.8)
Diagnosis
AML 44 (60.3)
MDS 29 (39.7)
No. of prior chemotherapy regimens
0 9 (12.3)
1 26 (35.6)
2 17 (23.3)
3 14 (19.2)
4 6 (8.2)
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CLABSI as a primary blood stream infection in a patient with
a CVC at the time of diagnosis or during the previous 48-hour
time period before blood stream infection diagnosis [6].
Clinicians differ in their identiﬁcation of infections as being
a CLABSI [7]. Furthermore, this original deﬁnition of CLABSI
(OCLABSI) includes pathogens that arise from sources unre-
lated to the presence of a central line, such as enteric gram-
negative bacilli and streptococcus viridans, as they likely
entered the bloodstream across compromised mucosal
barriers. We have therefore developed a modiﬁed CLABSI
deﬁnition (MCLABSI), which excludes these hospital-
associated blood stream infections [8]. MCLABSI includes
all of the pathogens under the NHSN deﬁnition of CLABSI
except Viridans group streptococci species in patients with
mucositis, and Enterococcus, Enterobacteriaceae, or Candida
species in patients with neutropenia or GVHD of the gut.
We estimated the incidence of OCLABSI and MCLABSI,
identiﬁed risk factors for OCLABSI, and assessed the impact
of OCLABSI and MCLABSI on survival in acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS)
patients undergoing HCT.6 1 (1.4)
Prior radiation therapy
Yes 3 (4.1)
No 70 (95.9)
Comorbidity score (HCT-CI)
Low (0) 11 (15.1)
Intermediate (1-2) 28 (38.4)
High (3þ) 34 (46.6)
Months from diagnosis to transplantation,
median (range)
6.2 (2.2-141.0)
Donor relationship
Unrelated 49 (67.1)
Sibling 24 (32.9)
HLA
Match 65 (89.0)
Mismatch 8 (11.0)
Transplantation type and cell source
MA e BM 34 (46.6)
MA e PSC 8 (11.0)METHODS
Patients and Assessment
All consecutive AML and MDS patients who underwent HCT from
August 2009 to December 2011 in the Cleveland Clinic Uniﬁed Transplant
Database were included in this study. Patients were treated on HCT proto-
cols that were reviewed and approved by the Cleveland Clinic’s Institutional
Review Board with signed informed consent obtained from all patients.
Patient and transplantation characteristics and outcomes were obtained
from the Uniﬁed Transplant Database.
The occurrence of OCLABSI andMCLABSI were identiﬁed and catalogued
in the Infection Prevention Database for this population. Diagnosis of CLABSI
under both deﬁnitions required identiﬁcation of a recognized pathogen on
at least 1 blood culture (or in 2 or more blood cultures drawn on separate
occasions if a common skin contaminant was isolated) as per NHSN
guidelines [9]. Incidence of CLABSI was identiﬁed using the criteria as
deﬁned above by members of the infection control team, who also recorded
the speciﬁc causative pathogen(s) and the time of diagnosis following HCT.MA e CBC 12 (16.4)
RIC e PSC 7 (9.6)
RIC e CBC 3 (4.1)
Mini-allogeneic e PSC 9 (12.3)
Preparative regimen
Bu/Cy 42 (57.5)
Cy/Flu/TBI 12 (16.4)
Flu/TBI 9 (12.3)
Bu/Flu 7 (9.6)
Flu/Cy/TBI/ATG 3 (4.1)
CD34þ dose  106/kg, median (range) 2.42 (0.01-10.01)
TNC dose  108/kg, median (range) 2.35 (0.19-16.33)
GVHD prophylaxis regimen
CSA/MMF 36 (49.3)
FK/MMF 11 (15.1)
FK/MTX 26 (35.6)
Worst mucositis during admission, WHO
grade (n ¼ 61)
0 9 (14.8)
1 21 (34.4)
2 14 (23.0)
3 15 (24.6)
4 2 (3.3)
Days until PMN  500/mL (n ¼ 66), median
(range)
15 (6-77)
Days until platelets  20,000 (n ¼ 62),
median (range)
20 (11-170)
Hospital stay, days (n ¼ 64), median (range) 29 (10-111)
Months of follow-up among living patients
(n ¼ 39), median (range)
15.0 (4.2-30.7)
(continued on next page)Statistical Analysis
OCLABSI and MCLABSI were estimated using the Kaplan-Meier method.
Cox proportional hazards analysis was used to identify risk factors for
OCLABSI and all-cause mortality; risk factor analysis for MCLABSI could not
be performed because of a limited number of events. Multivariable risk
factors were identiﬁed using stepwise Cox analysis with a variable entry
criterion of P .10 and a variable retention criterion of P .05. Cox results are
presented as the hazard ratio (HR), 95% CI, and corresponding P value.
Further assessment of OCLABSI risk factors included bootstrap analysis. One
thousand bootstrap samples of size 73 were selected with replacement from
the data. Cox analysis was done on each of the 1,000 samples, and results
were summarized as the percentage of times each variable occurred in the
bootstrap analyses. Variables that occurred in >50% of the bootstrap models
were considered signiﬁcant. Two models were calculated for mortality: one
that included OCLABSI and one that included MCLABSI.
Non-CLABSI variables used in all risk factor analysis included gender,
race, age, prior transplantation, diagnosis, number of prior chemotherapy
regimens, prior radiation therapy, comorbidity index (HCT-CI), donor rela-
tionship, human leukocyte antigen (HLA) match, recipient or donor cyto-
megalovirus (CMV) serostatus, months from diagnosis to transplantation,
transplantation type, cell source, CD34þ dose, and total nucleated cell (TNC)
dose. Neutrophil engraftment (absolute neutrophil count or ANC)500/mL3
was also analyzed as a risk factor for OCLABSI. In all risk factor analyses,
posttransplantation variables were analyzed as time-varying covariates.
Incidence of OCLABSI and MCLABSI were compared between cord blood
cells (CBC) and bone marrow (BM) and/or peripheral stem cells (PSC) using
the log-rank test. Days to OCLABSI, MCLABSI, and neutrophil engraftment
were compared using the Wilcoxon rank-sum test. Analyses were done
using SAS software (SAS Institute, Inc., Cary, NC). All statistical tests were
two-sided, and P  .05 was used to indicate statistical signiﬁcance.
Table 1
(continued)
Variable No. of Subjects
Posttransplantation events
100-d mortality 11 (15.1)
Relapse 19 (26.0)
Death 34 (46.6)
Cause of death (n ¼ 34)
Relapse 14 (41.2)
Infection 9 (26.5)
Nonpulmonary organ failure 5 (14.7)
Acute GVHD 3 (8.8)
Chronic GVHD 2 (5.9)
Pulmonary 1 (2.9)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome;
HCT-CI, hematopoietic cell transplantation comorbidity index; HLA, human
leukocyte antigen; MA, myeloablative; RIC, reduced-intensity conditioning;
BM, bone marrow; PSC, peripheral stem cells; CBC, cord blood cells;
Bu, busulfan; Cy, cyclophosphamide; Flu, ﬂudarabine; TBI, total body irra-
diation; ATG, anti-thymocyte globulin; TNC, total nucleated cell; CSA,
cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; PMN,
polymorphonuclear cells; GVHD, graft-versus-host disease.
Data are presented as n (%) unless otherwise noted.
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Patient Characteristics
A total of 149 patients, of whom 73 had AML or MDS,
underwent allogeneic hematopoietic cell blood or BM
transplantation from August 2009 to December 2011. The
baseline patient characteristics for these patients identiﬁed
with AML or MDS are summarized in Table 1. Among this
population, median age at HCTwas 52 years (range,16 to 70),
they had received a median of 2 prior chemotherapy regi-
mens, 6 had undergone previous transplantations, and 3 had
previous radiation therapy. The HCT-CI was low to interme-
diate (<3) in 39 patients (53%) and high (3) in 34 patients
(47%). HCT donors included 24 sibling and 49 unrelated
individuals; 54 HCT were myeloablative, and 19 were
reduced-intensity conditioning; and stem cell sources were
34 BM, 24 PSC, and 15 UCB. There was a median of 6.2
months (range, 2.2 to 141) between AML/MDS diagnosis and
HCT. The median CD34þ dose was 2.42  106/kg (range, 0.01
to 10.01) and TNC dose of 2.35108/kg (range, 0.19 to 16.33).
Median length of hospital stay was 29 days (n¼ 64; range,10
to 111), with 15 days until polymorphonuclear cells
(PMN) > 500 (n ¼ 66; range, 6 to 77), and 20 days until
platelets > 20,000 (n ¼ 62; range, 11 to 170).CLABSI Incidence and Causative Pathogens
Table 2 shows the prevalence and diagnosis of OCLABSI
andMCLABSI in the study population. Among the 73 patients
with AML or MDS, 23 (32%) developed CLABSI under the
standard NHSN deﬁnition, and 8 (11%) had MCLABSI
(Figure 1). Median onset was 9 days (range, 2 to 211) for
OCLABSI and 12 days (range, 5 to 176) for MCLABSI. Onset
varied depending on stem cell source: UCB recipientsTable 2
Prevalence and Onset of OCLABSI/MCLABSI and Days Until Neutrophil Engraftmen
Variable Overall (n ¼ 73) C
No. of OCLABSI (%) 23 (31.5) 1
Days after transplantation, median (range) 9 (2-211)
No. of MCLABSI (%) 8 (11.0)
Days after transplantation, median (range) 12 (5-176)
Days until PMN 500/mL, median (range) 15 (6-77) 2
OCLABSI indicates original deﬁnition central line-associated blood stream infection;
CBC, cord blood cells; BM, bone marrow; PSC, peripheral stem cells; PMN, polymodeveloped OCLABSI at a median of 5 days (range, 2 to 12),
whereas the BM and/or PSC recipients developed OCLABSI at
a median of 78 days (range, 7 to 211; P < .001). MCLABSI was
diagnosed less frequently (4 UCB and 4 BM and/or PSC);
however, with a similar discrepancy of 7 days (range, 5 to 12)
and 77 days (range, 13 to 176) for UCB and BM and/or PSC,
respectively (P ¼ .030). Time until PMN recovery was noted
to be 28 days (n ¼ 13; range, 19 to 77) for UCB and 14 days
(n ¼ 53; range, 6 to 24; P < .001) for BM/PSC.
Etiologies of OCLABSI included 11 enteric gram-negative
bacilli, 7 Streptococcus viridans group, 6 enterococcus (3
vancomycin resistant), 5 Staphylococcus epidermidis (3
methicillin resistant), 2 fungal species, 2 gram-positive
bacilli, 1 Pseudomonas, 1 other Streptococcus species, and 1
Stenotrophomonas. Pathogens isolated in MCLABSI included
5 Staphylococcal epidermidis (3 methicillin resistant), 2
Streptococcus viridans group, 2 gram-positive bacilli, 1 van-
comycin resistant, and 1 Pseudomonas. Four patients had
polymicrobial CLABSI including 2 MCLABSI, and 5 (all of
whom died) had more than one separately documented
CLABSI, 4 of which were MCLABSI. Table 3 shows the timing
and pathogen responsible in the 23 patients diagnosed with
OCLABSI and the 9 MCLABSI diagnosed in 8 patients.
Risk Factors for OCLABSI and Mortality
Univariable risk factor analysis for OCLABSI (Table 4)
revealed an association with cord blood transplantation
(P < .001), HLA-mismatch (P ¼ .005), low CD34þ count
(P ¼ .007), low TNC dose (P ¼ .016), and non-Caucasian race
(P ¼ .017). Risk factors for OCLABSI in multivariable analysis
were UCB (HR,14.19; CI, 5.41 to 37.18; P< .001) and high HCT-
CI (HR, 4.68; CI, 1.81 to 12.13; P ¼ .002). Bootstrap analysis
conﬁrmed the signiﬁcance of UCB and high HCT-CI in
multivariable analysis, which appeared in 91.3% and 72.0% of
1,000 bootstrap samples, respectively. Based on stem cell
source and HCT-CI, the risk of OCLABSI occurrence was
stratiﬁed into 4 distinct groups as shown in Figure 2.
In univariable analysis, mortality was strongly associated
with OCLABSI (HR, 3.72; CI 1.88 to 7.36; P < .001) and
MCLABSI (HR 2.96; CI, 1.27 to 6.89; P ¼ .012). Other uni-
variable risk factors for mortality included MDS diagnosis
(HR 3.08; CI, 1.53 to 6.19; P ¼ .002), age at transplantation
(HR, 1.65 per 10-year increase; CI, 1.18 to 2.30; P ¼ .003).
Multivariable analysis conﬁrmed the strong association of
OCLABSI (HR, 7.14; CI 3.31to 15.37; P < .001) and MCLABSI
(HR, 6.44; CI, 2.28 to 18.18; P< .001) withmortality, adjusting
forMDS diagnosis (HR, 5.21; P< .001 in themodel containing
OCLABSI; HR, 4.71, P < .001 in the MCLABSI model) and age
(HR, 1.81 per 10-year increase; P ¼ .004 OCLABSI model; HR,
1.60; P ¼ .009 MCLABSI model).
DISCUSSION
AML and MDS patients undergoing HCT are at high risk of
therapy-related morbidity and mortality. One of the greatestt by Stem Cell Source
BC (n ¼ 15) BM/PSC (n ¼ 58) P Value (CBC vs BM/PSC)
1 (73.3) 12 (20.7) <.001
5 (2-12) 78 (7-211) <.001
4 (26.7) 4 (6.9) .006
7 (5-12) 77 (13-176) .030
8 (19-77) 14 (6-24) <.001
MCLABSI, modiﬁed deﬁnition central line-associated blood stream infection;
rphonuclear cells.
Figure 1. Original and modiﬁed deﬁnition CLABSI after HCT (n ¼ 73). Of 73
AML/MDS patients, 23 (32%) developed CLABSI under the standard NHSN
deﬁnition, and 8 (11%) were diagnosed with MCLABSI. Median onset of
OCLABSI was 9 days (range, 2 to 211) versus 12 days (range, 5 to 176) for
MCLABSI.
Table 4
Univariable Risk Factors for OCLABSI in AML/MDS
Variable HR 95% CI P Value* Boot-
Strapy
Cell source 91.3%
BM/PSC 1.28 0.38-4.24 .69
CBC/PSC 10.26 3.21-32.82 <.001
CBC/PSC þ BM 8.79 3.77-20.51 <.001
Comorbidity score (HCT-CI) 72.0%
Intermediate/low 1.45 0.29-7.21 .65
High/low 3.65 0.83-16.10 .09
High/intermediate þ low 2.52 0.59-10.81 .21
Race 36.3%
Non-Caucasian/Caucasian 3.78 1.27-11.24 .017
Neutrophil engraftment 35.8%
Yes/No 0.30 0.06-1.54 .15
Prior transplantation 28.3%
Yes/No 2.65 0.78-8.97 .12
HLA 25.8%
Mismatch/match 4.34 1.57-12.03 .005
Recipient or donor CMV status 18.6%
Positive/negative 2.35 0.70-7.92 .17
Months from diagnosis to
transplantation
18.3%
Per 12-mo increase 1.01 0.81-1.25 .95
TNC dose,  108/kg 17.0%
Per 1  108/kg increase 0.78 0.64-0.96 .016
Transplantation type 11.4%
RIC/mini 1.26 0.18-9.00 .82
MA/mini 1.92 0.45-8.26 .38
Prior radiation therapy 7.2%
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potentially avoidable. We rigorously identiﬁed AML andMDS
HCT patients who developed blood stream infections, and
found that both the original NHSN-deﬁned CLABSI and our
modiﬁed CLABSI are strongly associated with mortality.Table 3
Diagnosis of OCLABSI/MCLABSI, Causative Organism, and Mortality
Outcome
HCT
Type
Day Causative Organism(s) FU
Day
FU Status Cause of
Death
MA 2 K. pneumoniae 49 Dead Infection
MA 3 K. pneumoniae 105 Dead Relapse
RIC 3 VRE 23 Dead Enterocolitis
MA 3 E. coli 605 Alive
MA 5 *GPB, S. haemolytica,
S. viridans, VRE
742 Alive
MA 5 S. viridans 382 Alive
MA 5 S. viridans 409 Alive
MA 5 Enterobacter spp. 93 Dead Acute GVHD
MA 6 *S. viridans 58 Dead Acute GVHD
50 *Clostridium spp.
MA 7 K. pneumoniae 226 Dead Relapse
114 K. pneumoniae, E. cloacae
135 E. cloacae
MA 7 E. coli 217 Dead Relapse
MA 9 *P. aeruginosa 68 Dead Multiorgan
failure59 Enterobacter spp.
MA 9 K. oxytoca 264 Dead Relapse
36 *MRSE
MA 11 R. mucilaginosa, S. mitis 165 Alive
RIC 12 *S. viridans 631 Dead Infection
MA 13 *MRSE 135 Dead Relapse
MA 65 C. tropicalis 78 Dead Infection
Mini 91 VRE 143 Dead Relapse
MA 118 *MRSE, S. viridans 376 Dead Relapse
140 Enterobacter spp.
MA 176 *S. epidermidis 186 Dead Relapse
Mini 200 E. coli, S. viridans 532 Alive
MA 201 E. cloacae 456 Alive
MA 211 S. maltophilia, VRE 274 Dead Acute MI
OCLABSI indicates original-deﬁnition central-line associated bloodstream
infection; MCLABSI, modiﬁed-deﬁnition central-line associated blood-
stream infection; HCT, hematopoietic cell transplantation; FU, follow-up;
MA, myeloablative; RIC, reduced-intensity conditioning; VRE, vancomycin-
resistant enterococcus; GPB, gram-positive bacilli; MRSE, methicillin-
resistant streptococcus epidermidis; GVHD, graft-versus-host disease; MI,
myocardial infarction.
* Incidences of MCLABSI.
Yes/no 1.08 0.15-8.07 .94
Gender 6.7%
Male/female 1.32 0.54-3.22 .54
Number of prior chemotherapy
regimens
6.2%
Per 1 regimen increase 1.34 0.97-1.84 .07
Diagnosis 6.1%
AML/MDS 2.46 0.91-6.66 .08
Donor relationship 5.6%
Unrelated/sibling 1.70 0.67-4.32 .27
CD34þ dose,  106/kg 5.5%
Per 1  106/kg increase 0.72 0.56-0.91 .007
Age at transplantation 4.6%
Per 10-year increase 1.05 0.75-1.47 .76
OCLABSI indicates original-deﬁnition central-line associated blood stream
infection; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome;
HR, hazard ratio; HCT-CI, hematopoietic cell transplantation comorbidity
index; BM, bone marrow; PSC, peripheral stem cells; CBC, cord blood cells;
HLA, human leukocyte antigen; TNC, total nucleated cells; RIC, reduced-
intensity conditioning; MA, myeloablative conditioning.
* .05 considered signiﬁcant.
y Percentage in 1,000 bootstrap analyses, >50% considered signiﬁcant.The bacterial ﬂora included in the MCLABSI deﬁnition
more accurately reﬂect blood stream infections acquired
secondary to CVC from known skin contaminants, elimi-
nating oropharyngeal and gastrointestinal ﬂora likely ob-
tained by translocation of these species across compromised
mucocutaneous surfaces, which are included in the OCLABSI
deﬁnition. Given its greater precision, we believe the
MCLABSI rate is the endpoint that should be measured when
analyzing the success of CLABSI prevention programs. We
documented that prevalence of MCLABSI was markedly less
than OCLABSI, as similarly seen in the study by DiGiorgio
et al. that originally redeﬁned CLABSI [8]. Finally, the NHSN
has modiﬁed their blood stream infections protocol to
account for mucosal surface injury [9].
Certain transplantation subpopulations are particularly
prone to CLABSI. Multivariable analysis revealed that high
HCT-CI and umbilical CBC source are associated with more
frequent CLABSI. HCT-CI is used during pretransplantation
evaluation to predict HCT outcome. The efﬁcacy of this
Figure 2. OCLABSI based on stem cell source and hematopoietic cord trans-
plantation comorbidity index (HCT-CI). Four distinct risk groups for OCLABSI
were found based on stem cell source (cord blood cells versus bone marrow/
peripheral stem cells) and HCT-CI (high versus intermediate/low).
J. Lukenbill et al. / Biol Blood Marrow Transplant 19 (2013) 720e724724index was recently evaluated prospectively, revealing
correlation with 2-year nonrelapse mortality and overall
survival, especially when the HCT-CI was 0-2. In AML and
MDS, the HCT-CI was found to be the best predictor of non-
relapse mortality [10]. In our study, high HCT-CI (3) was
associated with an HR of 3.65 (CI, 0.83 to 16.10; P ¼ .09) for
OCLABSI and an HR of 2.62 (CI, 0.87 to 7.87; P ¼ .09) for
mortality when compared to a low HCT-CI (0), stressing the
importance of careful assessment of comorbidities before
transplantation.
Numerous studies have found overall survival, relapse,
relapse-free survival, and transplantation-related mortality
using UCB comparable to those for PSC [11-13]. However, one
clear disadvantage in all these studies is delayed time to PMN
recovery compared to singly mismatched PSC, although
infection rates were comparable between the 2 stem cell
sources. Our study conﬁrmed delayed PMN recovery (28 days
for UCB versus 14 days for PSC) and also revealed increased
CLABSI rates in UCB recipients. Furthermore, OCLABSI
occurred earlier in patients undergoing UCB, with a median
onset of CLABSI at 5 days in UCB and 78 days in BM and/or PB.
Another study demonstrated similar delayed PMN recovery
time (29 days for UCB versus 14 days for PSC) and increased
early (<50 days) infections in UCB recipients [14]. Therefore,
extra vigilance is necessary in those receiving CBC, given
their increased susceptibility to CLABSI during prolonged
neutropenia.
Further pressure is added to CLABSI prevention programs
given the role of CLABSI as an institutional and individual
quality measure. CLABSI and its treatment increase the
economic burden on both the individual patient and our
health care system, costing $11,971 to $54,000 per case [5].
Hospitals have the obligation of reporting incidence of
CLABSI to the NHSN, as its occurrence affects compensation
by the Centers for Medicare & Medicaid Services. Further-
more, CLABSI rates are public knowledge as they are available
on the CMS website. These ﬁnancial incentives have led to
close internal surveillance of the occurrence of CLABSI and
the efﬁcacy of various preventative measures [15].
CONCLUSION
CLABSI is unfortunately common and often fatal in
patients with AML and MDS undergoing HCT, especially inCBC recipients with a higher HCT-CI. Improvements in the
current system of infection prevention depend on precise
deﬁnition of CLABSI to aid diagnosis, conﬁrm eradication,
and develop effective surveillance programs. We argue that
the MCLABSI deﬁnition more precisely identiﬁes the CVC as
the source of infection. Efforts to identify patients at highest
risk of CLABSI, careful adherence to preventative infectious
control measures, and design of methods to enhance
immune reconstitution following transplantation could
improve outcome in a substantial portion of patients.ACKNOWLEDGMENTS
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